ArticleMetabolic brain disease2026
Elucidating the pharmacological mechanism of Yangming-Kaixin-Yizhi formula in inhibiting neuronal ferroptosis via Nrf2 in Alzheimer's disease: a study combining network pharmacology, transcriptomics, and experimental validation.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic cell death networks in Alzheimer's disease: mechanistic links and therapeutic perspectives of ferroptosis, cuproptosis, and disulfidptosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is considered to be an important pathological driver of Alzheimer's disease (AD), and inhibiting neuronal ferroptosis shows a significant AD improvement effect. Yangming-Kaixin-Yizhi formula (YKY), a traditional Chinese medicine (TCM) formula, has been used for the treatment of forgetfulness for hundreds of years, but its mechanisms remain unclear. This study aimed to delineate the herb-component-target network of YKY in regulating ferroptosis for the treatment of AD, providing modern scientific basis for the traditional use of YKY. After 3×Tg-AD mice were orally treated with YKY for 11 weeks, the learning and memory ability of the mice was evaluated by Morris water maze, and hippocampal neuron loss was observed by hematoxylin-eosin (HE) staining. Transcriptomics and network pharmacology were used to analyze the underlying pharmacological mechanisms. Perls staining and immunofluorescence were used to observe brain iron deposition and hippocampal neuronal ferroptosis, respectively. The effects of YKY on iron deposition, reactive oxygen species (ROS) and lipid peroxidation in HT22 cells were detected by FerroOrange, DCFH-DA and BODIPY
Indexed as
Identifiers
41793523What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.